Latigo Biotherapeutics, Backed by QIA, Secures USD 150M to Tackle Pain Without Opioids

Latigo  What happened? Latigo Biotherapeutics closed USD 150 million in a series B funding round. The round was led by Blue Owl Capital with participation from many other investors. Most notably, the Qatar Investment Authority...